Matthew Anderson, MD, PhD

Dr Matthew Anderson, MD, PhD joined the Oxford-Harrington Rare Disease Centre as Co-Director in early 2025.

Dr Anderson brings an extraordinary depth of expertise to the OHC mission, with a background that bridges medicine, neuroscience, and biotechnology. He holds a BS in Chemistry from Cornell College, followed by an MD and PhD from the University of Iowa, where he studied medicine, physiology, and biophysics. His training in pathology and neuropathology took him from the University of Iowa Hospitals to Harvard Medical School, where he later became Chief of Neuropathology.

He joined OHC from a position as VP and Head, Neuroscience Therapeutic Focus Area at Regeneron Pharmaceuticals, leading a team of 45 scientists. He has also conducted pioneering research in neuroscience and immunology as a research fellow at MIT. 

Dr Anderson is also Sylvia K. Reitman Chair in Discovery and Innovation, and Senior Attending Physician at University Hospitals as well as Professor of Pathology at Case Western Reserve University.